---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Fri, Jul 25, 2008 at 11:44 PM
Subject: Prospective study of combined treatment with interferon-alpha and active vitamin D for Japanese patients with metastatic renal cell carcinoma.
To: mesothelioma77@gmail.com
[1]Int J Urol. 2008 Jul 21;
Obara W, Mizutani Y, Oyama C, Akaza H, Ishii N, Kohri K, Namiki M, Okuyama A, Shima H, Yokoyama M, Shuin T, Miki T, Watanabe Y, Fujioka T
Objectives: To assess the safety and efficacy of combined therapy with interferon-alpha (INF-alpha) and active vitamin D(3) for metastatic renal cell carcinoma (RCC). Methods: Sixteen patients with metastatic RCC were enrolled in this prospective study. All received oral alfacalcidol (1 microg once daily) and INF-alpha (Sumiferon; 3 million units, three times a week). The primary endpoint was the response rate (defined as complete + partial remission). Secondary endpoints were cancer-specific survival and toxicity. The median follow-up period was 17 months (range: 5-49 months). Results: The median age of the patients was 68 years (range: 41-73 years). The sites of metastases were: lung in 13 patients, bone in one, lung and bone in one, and lung, bone, and lymph nodes in one. Four patients (25%) had a partial response (PR), 10 patients (62.5%) showed no change (NC), and two patients (12.5%) had progressive disease (PD). The median cancer-specific survival time was 45 months. One patient had to discontinue vitamin D(3) because of hypercalcemia. Kaplan-Meier survival analysis revealed that metastasis at the time of initial diagnosis and older than average age were significant predictors of poor survival (P
___
Source: http://www.hubmed.org/display.cgi?uids=18651865
--
~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Fri, Jul 25, 2008 at 11:44 PM
Subject: Prospective study of combined treatment with interferon-alpha and active vitamin D for Japanese patients with metastatic renal cell carcinoma.
To: mesothelioma77@gmail.com
[1]Int J Urol. 2008 Jul 21;
Obara W, Mizutani Y, Oyama C, Akaza H, Ishii N, Kohri K, Namiki M, Okuyama A, Shima H, Yokoyama M, Shuin T, Miki T, Watanabe Y, Fujioka T
Objectives: To assess the safety and efficacy of combined therapy with interferon-alpha (INF-alpha) and active vitamin D(3) for metastatic renal cell carcinoma (RCC). Methods: Sixteen patients with metastatic RCC were enrolled in this prospective study. All received oral alfacalcidol (1 microg once daily) and INF-alpha (Sumiferon; 3 million units, three times a week). The primary endpoint was the response rate (defined as complete + partial remission). Secondary endpoints were cancer-specific survival and toxicity. The median follow-up period was 17 months (range: 5-49 months). Results: The median age of the patients was 68 years (range: 41-73 years). The sites of metastases were: lung in 13 patients, bone in one, lung and bone in one, and lung, bone, and lymph nodes in one. Four patients (25%) had a partial response (PR), 10 patients (62.5%) showed no change (NC), and two patients (12.5%) had progressive disease (PD). The median cancer-specific survival time was 45 months. One patient had to discontinue vitamin D(3) because of hypercalcemia. Kaplan-Meier survival analysis revealed that metastasis at the time of initial diagnosis and older than average age were significant predictors of poor survival (P
___
Source: http://www.hubmed.org/display.cgi?uids=18651865
--
~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc